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For patients who are receiving treatment with oral anticoagulants 
and require an elective operation or other invasive procedure, in-
terrupting anticoagulation is often required. Each year, this common 
clinical scenario affects approximately one in six patients on oral 
anticoagulation.1,2 The perioperative management of such patients 
is pertinent to many clinicians, including internists, surgeons, anes-
thetists, family physicians, and dentists.2,3
In this issue of RPTH, Shaw and colleagues provide data on the 
safety of perioperative interruption of direct oral anticoagulants 
(DOACs) for elective invasive procedures in patients with atrial fibril-
lation.4 The clinical scope of this problem is important. Not only are 
DOACs fast replacing vitamin K antagonists (VKAs) as anticoagulant 
treatment for stroke prevention in patients with atrial fibrillation,5 
but as a previous survey among medical practitioners showed, the 
effects of DOACs at time of invasive procedures are often unrec-
ognized.6 Previous expert narrative reviews have provided guidance 
to clinicians on the management of DOACs in the perioperative 
period,4and in order to update these expert reviews with clinical 
data, Shaw et al. conducted a systematic review and meta- analysis 
of the literature involving four cohort studies and four clinical tri-
als. They investigated in a total of 14 446 patients (who used a 
DOAC or VKA) the 30- day risk of thromboembolic events, bleed-
ing, and death. Unfortunately, of the eight studies included, three 
did not describe their perioperative anticoagulation protocols for 
DOACs, but the other five studies more or less did. For dabigatran 
these perioperative protocols were reasonably well described and 
they were based on the creatinine clearance, the corresponding 
estimated half- life of dabigatran (13- 27 hour depending on renal 
function),7,8 and on whether the invasive procedure was deemed as 
having a low or high risk of bleeding.1,9,10 For rivaroxaban, those who 
temporarily interrupted anticoagulant treatment for ≥3 days due to 
any cause were considered to have interrupted their treatment due 
to an invasive procedure.11 For apixaban, each procedure was classi-
fied as either “no interruption” (if the study drug was not interrupted 
or interrupted on the same day of the procedure) or “any interrup-
tion” (if the study drug was stopped between one and seven days 
before the procedure), but the final decision about when apixaban 
would be interrupted was left to local investigators.12 Therefore, we 
do not exactly know the perioperative management in the included 
apixaban and rivaroxaban studies.11,12 Also, none of these five stud-
ies took into account the thromboembolic risk of the patients during 
the perioperative phase, as is advised by the American College of 
Chest Physicians and other expert opinion panels.3,4 Furthermore, 
from the apixaban study it was unclear if for procedures with min-
imal bleeding risk, like dental or ocular procedures, apixaban was 
interrupted or not,13 while for the rivaroxaban and dabigatran stud-
ies in at least some of these situations anticoagulation therapy was 
interrupted.9–12 This is important to note because expert opinion 
panels advise not to interrupt anticoagulation in minimal bleeding 
risk procedures.2,3 Nevertheless, Shaw et al. had to make do with 
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what information they had and with it they found that the 30- day 
risk for thromboembolic and major bleeding events was 0.4% and 
1.8%, respectively. Based on these absolute risks the authors rightly 
conclude that these findings seem reassuring. However, despite the 
large number of patients involved and the meticulous systematic 
review and meta- analysis that the authors performed, this study 
should not be seen as an endpoint but as a starting point, which is 
also urged by the authors at the end of their discussion.4 Below, we 
discuss some issues that should prompt more clinically oriented re-
search in this field with predefined endpoints, and propose a proto-
col for DOAC interruption that seems reasonable with the evidence 
that is presently known (Table 1).
1  | GENER ALIZ ABILIT Y
Of the eight studies that were meta- analyzed, four involved pa-
tients who were included in randomized clinical trials (n = 9939).4 
Previous studies have shown that VKAs are often prescribed to 
patients who would not have qualified for clinical trials,13 which is 
likely to be the same for patients who are prescribed a DOAC.14 
Randomized trials prioritize internal over external validity, and re-
searchers therefore strive to include patients who, for instance, are 
more likely to adhere to the prescribed procedures, are not likely to 
undergo major surgery, have a life- expectancy longer than the trial 
duration, and are capable of giving informed consent. This is a rea-
sonable approach that is needed before one can even start thinking 
about the more heterogeneous real world.14 In the meta- analysis, 
Shaw et al. did include patients with atrial fibrillation on DOAC who 
had an invasive procedure outside clinical trial settings, but these 
comprised only 7% (n = 679) of the total study population (ie, all 
other patients came from clinical trials). Therefore, it can be ques-
tioned whether the relatively low outcome rates of thromboem-
bolic and major bleeding events at 30- days post invasive procedure 
are due to a safe interruption strategy only. Large observational 
studies that include consecutive patients with atrial fibrillation on 
DOAC and who require an elective invasive procedure are needed 
to address this issue.
2  | HIGH BLEEDING RISK INVA SIVE 
PROCEDURES
Of the eight studies included, there were three that exclusively 
concerned patients undergoing permanent pacemaker insertion or 
implantable cardioverter defibrillator procedures. These invasive 
procedures are considered to have a minimal bleeding risk and in 
which anticoagulation can be continued during the procedure.2,3 
It is therefore not surprising that in these studies none of the pa-
tients developed a thromboembolic event or (when reported) 
a major bleeding. But also in the other five studies that included 
patients undergoing a variety of procedures, the large majority of 
patients underwent procedures that are considered to be minimal/
low bleeding risk procedures. The clinically relevant procedures 
where the major bleeding risk is high (ie, ≥2% within two days post- 
surgery), like surgery with extensive tissue injury, cancer surgery, 
joint arthroplasty, or reconstructive plastic surgery,2,3 are under-
represented in the meta- analysis. It is unfortunate that the au-
thors did not have access to individual patient data as this might 
have answered the question what the postoperative bleeding- and 
TABLE  1 Proposed protocol for DOAC interruption at time of an invasive procedurea
DOAC type
Estimated Bleeding risk Interruption timing of DOAC
half- life, h of the procedure Day - 4 Day - 3 Day - 2 Day - 1 Day 0 Day +1 Day +2 Day +3
Dabigatran (eGFR 
≥ 50 ml/min)
High stop stop stop stop stopc restart
≈ 13- 15 h Low stop stop restart
 Minimal continueb
Dabigatran (eGFR 
< 50 ml/min)
High stop stop stop stop stop stop stopc restart
≈ 18- 27 h Low stop stop stop stop restart
 Minimal continueb
Rivaroxaban ≈ 5- 9 h High stop stop stop stop stopc restart
Low stop stop restart
 Minimal continueb
Apixaban ≈ 12- 17 h High stop stop stop stop stopc restart
Low stop stop restart
 Minimal continueb
DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate.
Definitions of which procedures are associated with minimal, low and high bleeding risks can be found in Ref. 4.
aAdapted from the PAUSE protocol,17 with some modifications (i.e, addition of minimal bleeding risk category).
bMay consider interrupting DOAC therapy on the day of the procedure.
cMay consider to restart DOAC therapy two days after the procedure.
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thromboembolic risk is in patients who underwent an elective high 
bleeding risk invasive procedure. Future studies should include 
larger numbers of patients who undergo such high bleeding risk 
procedures.
3  | TO ME A SURE OR NOT TO ME A SURE
As acknowledged by the authors, the results they found need 
validation in large prospective management studies where pre-
operative DOAC levels are also measured. Although not reported 
for apixaban and rivaroxaban, dabigatran levels are related with 
bleeding.15 There is a paucity of studies that actually looked at di-
rect oral anticoagulation levels at time of an invasive procedure; to 
our knowledge there is currently only one study available that ad-
dressed this issue.16 In this cohort study (which was a sub- analysis 
from one of the cohort studies that was reported in the meta- 
analysis9), performed by Douketis and colleagues, it was shown 
that in 181 patients who took dabigatran and were requesting an 
elective invasive procedure, the anticoagulant effect had not worn 
off in all patients despite that they withheld dabigatran therapy for 
24- 48 hours before the procedure. Approximately 15% had residual 
dabigatran levels at time of the procedure.16 As acknowledged by 
the authors, their study was unable to show that their strategy was 
necessarily safe, even though only one major bleed occurred in a 
patient in whom no anticoagulant effect was observed. Probably 
this issue is best explained by a number needed to harm (NNH), 
which calculates the number of patients that should be treated with 
dabigatran to produce one major bleed, opposed to patients who 
were unexposed to therapeutic dabigatran levels at the time of the 
procedure. We calculated that even for a NNH of 20 one would 
need a study of approximately 500 patients. The fact that the afore-
mentioned study was underpowered to find even a NNH of 20 is 
important, as it bears forward the need for a larger study where 
preoperative DOAC levels are measured.
4  | STANDARD OF C ARE APPROACH, 
E VIDENCE-  BA SED
Recently, the design and rationale of the Perioperative Anticoagulant 
Use for Surgery Evaluation (PAUSE) study for patients on a DOAC who 
need elective surgery or an invasive procedure has been published.17 
PAUSE will study in an observational design with longitudinal fol-
low- up if a standardized, patient- specific perioperative management 
tool for patients on DOACs with atrial fibrillation works in terms of 
safety and efficacy, and has a secondary aim to determine the effect 
of residual anticoagulation at time of the procedure. Initiatives like 
PAUSE are urgently needed.
In conclusion, the current study of Shaw et al. adds some scien-
tific support for safe interruption of anticoagulation in patients who 
are treated with DOACs and require elective surgery or an invasive 
procedure. Nevertheless, what the best perioperative management 
is in such patients is still uncertain.
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